RecruitingPhase 1NCT06952634
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
A Phase 1, Open Label, Single Dose Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of ESK001
Sponsor
Alumis Inc
Enrollment
48 participants
Start Date
Apr 29, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria2
- Body mass index between 18.0 and 40.0 kg/m2
- Diagnosis of chronic (> 6 months), stable hepatic impairment with no clinically significant changes within 30 days prior to dosing, as determined by medical history
Exclusion Criteria7
- Uncontrolled treated/untreated hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 105 mmHg), or uncontrolled treated/untreated hypotension (systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg), or resting pulse rate < 45 or > 100 bpm. Measurements may be repeated once in order to determine eligibility
- Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator or designee.
- Positive hepatitis panel and/or positive human immunodeficiency virus test.
- History of any uncontrolled or unstable renal, hematological, gastrointestinal, neurological, endocrine, or psychiatric disorder, as determined by the investigator or designee, within 6 months prior to screening.
- History or current diagnosis of uncontrolled or significant cardiac disease indicative of a significant risk of safety for participation in the study.
- Liver function tests outside the appropriate reference ranges that are not consistent with hepatic dysfunction, as determined by the investigator or designee.
- QTcF > 480 ms for males or > 490 ms for females at screening or check-in, as confirmed from the mean of the original value and 2 repeats.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGESK-001
Single oral dose of ESK-001 in participants from all cohorts
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06952634
Related Trials
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
NCT070233543 locations
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
NCT075467604 locations
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
NCT069113202 locations
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
NCT071441114 locations
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
NCT069972763 locations